pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ADARx Pharmaceuticals Inc · news · pharmadog
← back to ADARx Pharmaceuticals Inc
News mentioning ADARx Pharmaceuticals Inc
20
stories
7d
2026 Q3 Job Market Report: Job opportunities, layoffs show YOY improvement
biospace
26d
This week in charts: a big year for RNAi developers
biopharma dive
27d
Biotech notches 31 IPOs already this year, with 4 more joining queue
biospace
Oct 20, 26
Alnylam bulls and bears fight it out after business-shaking guidance cut
biospace
Oct 16, 26
City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipeline
biospace
Oct 16, 26
City goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to Nasdaq
fiercebiotech
Oct 15, 26
OrbiMed’s largest-ever Asian fund contributes to $3B war chest
fiercebiotech
Oct 9, 26
TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms
biospace
Oct 7, 26
TCGX launches $600M fund to bankroll Asian biotechs
fiercebiotech
Oct 6, 26
TRex Bio stomps toward $111M IPO, as Retension and Lycia also gear up to go public
fiercebiotech
Sep 25, 26
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
biospace
Sep 25, 26
Alnylam alumni lead RNAi biotech City Therapeutics to IPO filing
endpoints
Sep 25, 26
ADARx prices $446.3M Nasdaq debut, continuing industry's IPO momentum
endpoints
Sep 25, 26
ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
fiercebiotech
Sep 25, 26
RNAi drug specialist ADARx raises $446M IPO
biopharma dive
Sep 22, 26
2026 IPO blitz continues with 4 new biotech filings
biospace
Sep 21, 26
ADARx targets $319M IPO as TRexBio, Retension join filing queue
endpoints
Sep 8, 26
Moonwalk reloads with $70M and new RNAi prospects for obesity
biopharma dive
Sep 6, 26
AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
fiercebiotech
Sep 5, 26
AbbVie-allied ADARx aims for IPO with three drugs in the clinic
endpoints